Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Navamedic ASA ( (DE:N1A) ) has shared an announcement.
Navamedic ASA reported a 12.9% increase in revenues for the third quarter of 2025, driven by growth across its business areas and the acquisition of the dne pharma business, which contributed to the Rx segment. The acquisition enhances Navamedic’s position in the addiction treatment market, aligning with its growth strategy towards achieving NOK 1 billion in revenues, despite facing a slight operating loss due to amortization costs.
More about Navamedic ASA
Navamedic ASA is a Nordic pharmaceutical company focused on improving quality of life by supplying high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. The company addresses public health concerns such as obesity, Parkinson’s disease, antibiotics, and metabolism, and is known for its local insight and competence in the Nordic and Benelux regions. Navamedic is listed on the Oslo Stock Exchange and is headquartered in Oslo, Norway.
Average Trading Volume: 91,938
Current Market Cap: NOK532.4M
Find detailed analytics on N1A stock on TipRanks’ Stock Analysis page.